Market Place
Sourcing Support
Soligenix Reveals Long-Term Stability of Ebola Protein Vaccines
04 Sep 2025 //
PR NEWSWIRE
Soligenix to Present at H.C. Wainwright Global Conference
02 Sep 2025 //
PR NEWSWIRE
FDA Designates Soligenix Drug Orphan Status for Behçet`s Disease
18 Aug 2025 //
PR NEWSWIRE
Soligenix Reports Q2 2025 Financial Results and Recent
14 Aug 2025 //
PR NEWSWIRE
Rare Disease Clinical Progress Boosts Long-Term Revenue Potential
07 Aug 2025 //
PR NEWSWIRE
Soligenix Platform Targets Growing CTCL Therapy Demand
07 Aug 2025 //
GLOBENEWSWIRE
Soligenix Platform Provides Novel Treatment for Underserved CTCL
05 Aug 2025 //
GLOBENEWSWIRE
Ph 2 Trial Shows SGX945`s Efficacy in Treating Behçet`s Disease
31 Jul 2025 //
PR NEWSWIRE
Soligenix Corporate Update: Key Highlights and Future Milestones
09 Jul 2025 //
PR NEWSWIRE
Soligenix Manufactures Synthetic Hypericin at Sterling Pharma
01 Jul 2025 //
PR NEWSWIRE
Soligenix Highlights Dr. Ellen Kim`s Q&A and HyBryte™ in Clinical
06 Jun 2025 //
GLOBENEWSWIRE
Soligenix Announces Q1 2025 Financial Results
09 May 2025 //
PR NEWSWIRE
HyBryte™ Clinical Results Show Continued Post-Treatment Improvement
02 Dec 2024 //
PR NEWSWIRE
Soligenix Launches Phase 2 Trial for SGX945 in Behçet`s Disease
14 Nov 2024 //
PR NEWSWIRE
Soligenix Announces Recent Accomplishments & Q3 Financial Results
08 Nov 2024 //
PR NEWSWIRE
Soligenix, Inc. to Present at the 2024 ThinkEquity Conference
24 Oct 2024 //
GLOBENEWSWIRE
Soligenix Receives Hong Kong Patent For Synthetic Hypericin
22 Oct 2024 //
PR NEWSWIRE
Soligenix Announces Partnership with Sterling Pharma Solutions
03 Oct 2024 //
PR NEWSWIRE
Soligenix Receives European Patent for Synthetic Hypericin Production
03 Sep 2024 //
PR NEWSWIRE
Soligenix Announces Positive Clinical Results for HyBryte™ in CTCL Treatment
25 Jun 2024 //
PR NEWSWIRE
Soligenix Announces Reverse Stock Split
31 May 2024 //
PR NEWSWIRE
Soligenix Q1 2024 Financials, Accomplishments
10 May 2024 //
PR NEWSWIRE
Soligenix to Present at Upcoming Conferences
06 May 2024 //
PR NEWSWIRE
Soligenix extends patent protection for its Filovirus vaccine to UK&South Africa
27 Apr 2024 //
PHARMABIZ
Soligenix Extends Filovirus Vaccine Patent Protection to UK, S.Africa
25 Apr 2024 //
PR NEWSWIRE
Soligenix Announces Pricing of $4.75 Million Public Offering
18 Apr 2024 //
PR NEWSWIRE
FDA Grants Soligenix Orphan Drug For Marburg Prevention, Prophylaxis
15 Apr 2024 //
PR NEWSWIRE
Soligenix Granted FDA Orphan Drug Designation for SuVax Active Ingredient
11 Apr 2024 //
PR NEWSWIRE
FDA Grants Soligenix Orphan Status For Sudan Ebolavirus
11 Apr 2024 //
PR NEWSWIRE
Soligenix Announces Recent Accomplishments and Year End 2023 Financial Results
15 Mar 2024 //
PR NEWSWIRE
Soligenix Announces Formation of Behçet`s Disease Medical Advisory Board
08 Feb 2024 //
PR NEWSWIRE
Soligenix to Present at The Microcap Conference
25 Jan 2024 //
PR NEWSWIRE
FDA Grants Soligenix "Fast Track" Designation for Dusquetide
08 Jan 2024 //
PRESS RELEASE
Soligenix Announces Top-line Results of the Phase 2a Study of SGX302
04 Jan 2024 //
PR NEWSWIRE
Soligenix Announces Publication Showing Protection Against Filovirus Disease
02 Jan 2024 //
PR NEWSWIRE
Soligenix, Inc. Announces Adjournment of Annual Meeting
20 Oct 2023 //
PR NEWSWIRE
Soligenix Announces Achievement of Two-Year Stability with Bivalent Vaccines
25 Sep 2023 //
PR NEWSWIRE
Soligenix Announces Accomplishments And Second Quarter 2023 Financial Results
21 Aug 2023 //
PR NEWSWIRE
Soligenix Announces Expansion of SGX302 Ph2a in Mild-to-Moderate Psoriasis
11 Jul 2023 //
PR NEWSWIRE
Soligenix Announces European Patent Grant for Use of Dusquetide Oral Mucositis
16 May 2023 //
PR NEWSWIRE
Soligenix Announces Recent Accomplishments And 1Q 2023 FYR Results
15 May 2023 //
PR NEWSWIRE
Soligenix Announces Scheduling of Type A Meeting with the U.S. FDA to Review
11 May 2023 //
PR NEWSWIRE
Soligenix Announces Closing of $8.5 Million Public Offering
09 May 2023 //
PR NEWSWIRE
Soligenix Announces Appointment of Timothy R. Coté, M.D. to its BOD
03 May 2023 //
BUSINESSWIRE
Soligenix Enters into Exclusive Option Agreement with Silk Road Therapeutics
01 May 2023 //
PR NEWSWIRE
Soligenix Submits Type A Meeting Request to Review Study Evaluating HyBryte
24 Apr 2023 //
PR NEWSWIRE
Soligenix shares take another dip as FDA requests 2nd trial
15 Apr 2023 //
FIERCE BIOTECH
Soligenix Receives USAN Approval for "Hypericin Sodium" as Nonproprietary Name
05 Apr 2023 //
PR NEWSWIRE
Soligenix Announces Scheduling of Type A Meeting with the U.S. FDA for HyBryte
03 Apr 2023 //
PR NEWSWIRE
Soligenix Announces Recent Accomplishments And Year-End 2022 Financial Results
31 Mar 2023 //
PR NEWSWIRE
Soligenix Submits Type A Meeting Request to U.S. FDA for HyBryte NDA
09 Mar 2023 //
PR NEWSWIRE
Soligenix stock sinks as FDA refuses lymphoma application
15 Feb 2023 //
FIERCE BIOTECH
Soligenix Announces Reverse Stock Split
09 Feb 2023 //
PR NEWSWIRE
Soligenix Invited to Present at the Virtual Investor Summit Event
19 Jan 2023 //
PR NEWSWIRE
Soligenix Announces Distribution of Series D Preferred Stock
23 Dec 2022 //
PR NEWSWIRE
Soligenix opens patient enrolment for Phase IIa trial of psoriasis therapy
19 Dec 2022 //
CLINICALTRIALSARENA
Soligenix opens patient enrolment for Phase IIa trial of psoriasis therapy
19 Dec 2022 //
CLINICALTRIALSARENA
Soligenix Announces Submission of New Drug Application to the FDA for HyBryte
15 Dec 2022 //
PRNEWSWIRE
Soligenix to Receive $1.2 M in Non-Dilutive Funding
15 Nov 2022 //
PRNEWSWIRE
Soligenix Announces Adjournment of Annual Meeting
20 Oct 2022 //
PRNEWSWIRE
